Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation

Indian Journal of Psychiatry

Volumn 57, Issue , 2015, Pages 354-371

  Ram, Daya ^a   Gandotra, Sachin ^a  

^a CENTRAL INSTITUTE OF PSYCHIATRY   (India)

Author keywords

Antidepressants; anxiolytics; birth outcomes; lactation; pregnancy; psychotropic

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLONAZEPAM; DIAZEPAM; HYPNOTIC AGENT; LORAZEPAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VILAZODONE;

ANUS ATRESIA; ANXIETY DISORDER; APNEA; BEHAVIOR DISORDER; CLEFT LIP; CLINICAL DECISION MAKING; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CONGENITAL HIP DISLOCATION; CONGENITAL MALFORMATION; CONGENITAL STRABISMUS; CRYPTORCHISM; CYANOSIS; DOWN SYNDROME; DRUG ABSORPTION; DRUG HALF LIFE; DRUG INFORMATION; DRUG SAFETY; ELIMINATION HALF-LIFE; HEART SEPTUM DEFECT; HUMAN; HYPOSPADIAS; HYPOTHERMIA; INGUINAL HERNIA; LACTATION; LETHARGY; LIPOMENINGOCELE; MICROCEPHALY; MUSCLE HYPOTONIA; NONHUMAN; OUTCOME ASSESSMENT; PARALYTIC ILEUS; PATENT DUCTUS ARTERIOSUS; PERINATAL DEPRESSION; PIERRE ROBIN SYNDROME; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DRUG EXPOSURE; PYLORUS STENOSIS; RESPIRATION DEPRESSION; REVIEW; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TERATOGENESIS; TERATOGENICITY; TRACHEOESOPHAGEAL FISTULA; UMBILICAL HERNIA; ENZYME INHIBITION; FEMALE; FETUS RISK; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL EXPOSURE; RISK FACTOR; STOMACH EMPTYING;

EID: 84938328241     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.161504     Document Type: Review

References (228)

1. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and Practice of Psychopharmacotherapy. 3rd ed. Philadelphia: Lippincott, William and Wilkins; 2001.
2. Miller LJ. Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatr Med 1991;9:275-98.
3. Miller LJ. Pharmacotherapy during the perinatal period. The Hatherleigh Guide to Psychopharmacology. New York: Hatherleigh Press; 1999.
4. Wintz CJ. Difficult decisions: Women of childbearing age, mental illness, and psychopharmacologic therapy. J Am Psychiatr Nurses Assoc 1999;5:5-14.
5. Stowe ZN, Strader J, James R, Nemeroff CB. Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, Inc; 1998.
6. Gjere NA. Psychopharmacology in pregnancy. J Perinat Neonatal Nurs 2001;14:12-25.
7. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-2.
8. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Committee on Drugs. American Academy of Pediatrics. Pediatrics 2000;105 (4 Pt 1):880-7.
9. Ward RM. Pharmacology of the maternal?placental?fetal?unit and fetal therapy. Prog Pediatr Cardiol 1996;5:79-89.
10. Kerns LL. Treatment of mental disorders in pregnancy. A review of psychotropic drug risks and benefits. J Nerv Ment Dis 1986;174:652-9.
11. Shader RI, Greenblatt DJ. More on drugs and pregnancy. J Clin Psychopharmacol 1995;15:1-2.
12. Pastuszak A, Schick?Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first?trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8.
13. Meltolan MW. Take two aspirin tablets or not? Risk of medication use during pregnancy. Mother Baby J 1999;4:25-32.
14. Sachdeva P, Patel BG, Patel BK. Drug use in pregnancy; a point to ponder! Indian J Pharm Sci 2009;71:1-7.
15. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: An update. Psychiatr Clin North Am 2003;26:547-62.
16. Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 2008;57:1-5.
17. Langman J. Human development?normal and abnormals. In: Langman J, editor. Medical Embryology. Baltimore: Williams and Wilkins; 1985. p. 123.
18. Moore K, Persaud T. The Developing Human: Clinically Oriented Embryology. Philadelphia: W.B. Saunders; 1993.
19. Newport DJ, Wilcox MM, Stowe ZN. Antidepressants during pregnancy and lactation: Defining exposure and treatment issues. Semin Perinatol 2001;25:177-90.
20. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995;28:235-69.
21. Altshuler LL, Hendrick VC. Pregnancy and psychotropic medication: Changes in blood levels. J Clin Psychopharmacol 1996;16:78-80.
22. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996;153:592-606.
23. Sjoqvist F, Bergfors PG, Borga O, Lind M, Ygge H. Plasma disappearance of nortriptyline in a newborn infant following placental transfer from an intoxicated mother: Evidence for drug metabolism. Br J Clin Pharmacol 1972;80:496-500.
24. Heikkine T, Ekblad U, Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG 2002;109:1003-8.
25. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-6.
26. Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ. Placental passage of tricyclic antidepressants. Biol Psychiatry 2006;59:287-90.
27. Giudici V, Pogliani L, Cattaneo D, Dilillo D, Zuccotti GV. Serotonin reuptake inhibitors in pregnancy: Can genes help us in predicting neonatal adverse outcome? Biomed Res Int 2014;2014:276918.
28. Cohen L, Altshuler L. Pharmacologic management of psychiatric illness during pregnancy and the postpartum period. In: Rosenbaum J, editor. Psychiatric Clinics of North America: Annual of Drug Therapy. Philadelphia: WB Saunders; 1997. p. 21-60.
29. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: The Motherisk experience. J Psychiatry Neurosci 1997;22:192-6.
30. McElhatton PR, Garbis HM, Eléfant E, Vial T, Bellemin B, Mastroiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-94.
31. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: A preliminary report. Int J Psychiatry Med 1991;21:157-71.
32. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J (Clin Res Ed) 1982;284:1837-8.
33. Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 1973;2:680.
34. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991;29:479-84.
35. Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973;2:318-9.
36. Bromiker R, Kaplan M. Apparent intrauterine fetal withdrawal from clomipramine hydrochloride. JAMA 1994;272:1722-3.
37. Ter Horst PG, Jansman FG, van Lingen RA, Smit JP, de Jong?van den Berg LT, Brouwers JR. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv 2008;63:267-79.
38. Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: How about the newborn? Neuropsychiatr Dis Treat 2013;9:1257-66.
39. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: A critical review focused on risks and controversies. Acta Psychiatr Scand 2013;127:94-114.
40. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980;97:308-10.
41. Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972;81:570-2.
42. Ali SF, Buelke?Sam J, Newport GD, Slikker W Jr. Early neurobehavioral and neurochemical alterations in rats prenatally exposed to imipramine. Neurotoxicology 1986;7:365-80.
43. Vorhees CV, Brunner RL, Butcher RE. Psychotropic drugs as behavioral teratogens. Science 1979;205:1220-5.
44. Vernadakis A, Parker KK. Drugs and the developing central nervous system. Pharmacol Ther 1980;11:593-647.
45. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
46. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace?Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective, controlled study. Am J Psychiatry 2002;159:1889-95.
47. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-61.
48. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: A meta?analytical review of epidemiological studies. Psychol Med 2000;30:89-94.
49. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
50. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996-1000.
51. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-20.
52. Reller MD, Strickland MJ, Riehle?Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008;153:807-13.
53. Källén B, Nilsson E, Olausson PO. Antidepressant use during pregnancy: Comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol 2011;67:839-45.
54. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re?uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-8.
55. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010;121:471-9.
56. Kulin NA, Pastuszak A, Sage SR, Schick?Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 1998;279:609-10.
57. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30.
58. Cohen LS, Rosenbaum JF. Fluoxetine in pregnancy [letter]. N Engl J Med 1997;336:872.
59. Robert E. Treatment depression in pregnancy. N Engl J Med 1996;335:1056-8.
60. Ericson A, Källén B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-8.
61. Inman W, Kobotu K, Pearce G, Wilton L. Prescription event monitoring of paroxetine. PEM Reports 1993;1206:1-44.
62. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention Study. Use of selective serotonin?reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92.
63. Louik C, Lin AE, Werler MM, Hernández?Díaz S, Mitchell AA. First?trimester use of selective serotonin?reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
64. Wogelius P, Nørgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701-4.
65. Bakker MK, De Walle HE, Wilffert B, de Jong?Van den Berg LT. Fluoxetine and infantile hypertrophic pylorus stenosis: A signal from a birth defects?drug exposure surveillance study. Pharmacoepidemiol Drug Saf 2010;19:808-13.
66. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol Med 2010;40:1723-33.
67. Diav?Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, et al. Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
68. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111-20.
69. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population?based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76.
70. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nørgaard M. Use of selective serotonin?reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. Clin Epidemiol 2010;2:29-36.
71. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ 2009;339:b3569.
72. Bérard A, Ramos E, Rey E, Blais L, St?André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27.
73. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:961-6.
74. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Can J Psychiatry 2009;54:242-6.
75. Einarson A, Choi J, Koren G, Einarson T. Outcomes of infants exposed to multiple antidepressants during pregnancy: Results of a cohort study. J Popul Ther Clin Pharmacol 2011;18:e390-6.
76. Ramos E, St?André M, Rey E, Oraichi D, Bérard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008;192:344-50.
77. Wisner KL, Sit DK, Hanusa BH, Moses?Kolko EL, Bogen DL, Hunker DF, et al. Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557-66.
78. Klieger?Grossmann C, Weitzner B, Panchaud A, Pistelli A, Einarson T, Koren G, et al. Pregnancy outcomes following use of escitalopram: A prospective comparative cohort study. J Clin Pharmacol 2012;52:766-70.
79. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 2005;173:1320-1.
80. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075-85.
81. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta?analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-70.
82. Bar?Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, et al. Paroxetine and congenital malformations: Meta?analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-26.
83. Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: Focus on paroxetine. J Clin Psychiatry 2009;70:414-22.
84. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: A meta?analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-7.
85. O'Brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 2008;30:696-701.
86. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: A meta?analysis of clinical trials. Reprod Toxicol 2006;22:571-5.
87. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993;92:721-2.
88. Kwon P, Lefkowitz W. Poor neonatal adaptation in term infant. Fluoxetine toxicity. Pediatr Ann 2008;37:131-3.
89. Mhanna MJ, Bennet JB 2nd, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997;100:158-9.
90. Mohan CG, Moore JJ. Fluoxetine toxicity in a preterm infant. J Perinatol 2000;20:445-6.
91. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001;84:F134-5.
92. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32.
93. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry 1997;171:391-2.
94. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91.
95. Boucher N, Bairam A, Beaulac?Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol 2008;28:334-9.
96. Herbst F, Gortner L. Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy? Z Geburtshilfe Neonatol 2003;207:232-4.
97. Galbally M, Lewis AJ, Lum J, Buist A. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: Prospective controlled study. Aust N Z J Psychiatry 2009;43:846-54.
98. Suri R, Altshuler L, Hendrick V, Rasgon N, Lee E, Mintz J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004;7:193-200.
99. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: A prospective controlled cohort study. BJOG 2008;115:283-9.
100. Consortium on Safe Labor, Hibbard JU, Wilkins I, Sun L, Gregory K, Haberman S, et al. Respiratory morbidity in late preterm births. JAMA 2010;304:419-25.
101. Administration. UFAD. FDA Medwatch Drug Alert on Effexor (venlafaxine HCL) and Effecor XR (venlafaxine HCL); 2004. Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154975. htm.[Last cited on 2011 Dec 22].
102. Chambers CD, Hernandez?Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin?reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87.
103. Källén B, Olausson PO. Maternal use of selective serotonin re?uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801-6.
104. Heritage CK, Cunningham MD. Association of elective repeat cesarean delivery and persistent pulmonary hypertension of the newborn. Am J Obstet Gynecol 1985;152:627-9.
105. Hernández?Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007;120:e272-82.
106. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. BMJ 2012;344:d8012.
107. Administration USFAD. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. [Last accessed on 2015 Mar 07]. [12/4/11 ed].
108. Hallberg P, Sjöblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast?feeding: A review and clinical aspects. J Clin Psychopharmacol 2005;25:59-73.
109. Weikum WM, Oberlander TF, Hensch TK, Werker JF. Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc Natl Acad Sci U S A 2012;109 Suppl 2:17221-7.
110. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: Population based case?control study. BMJ 2013;346:f2059.
111. Simpson KL, Weaver KJ, de Villers?Sidani E, Lu JY, Cai Z, Pang Y, et al. Perinatal antidepressant exposure alters cortical network function in rodents. Proc Natl Acad Sci U S A 2011;108:18465-70.
112. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, Mass: Publishing Science Group; 1977.
113. Gracious BL, Wisner KL. Phenelzine use throughout pregnancy and the puerperium: Case report, review of the literature, and management recommendations. Depress Anxiety 1997;6:124-8.
114. Grover S, Avasthi A, Sharma Y. Psychotropics in pregnancy: Weighing the risks. Indian J Med Res 2006;123:497-512.
115. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI, et al. Newer antidepressants in pregnancy: Prospective outcome of a case series. Reprod Toxicol 2004;19:235-8.
116. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27:607-13.
117. Saks BR. Mirtazapine: Treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient: A report of 7 cases. Arch Womens Ment Health 2001;4:165-70.
118. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav?Citrin O, et al. Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280-4.
119. Einarson A, Bonari L, Voyer?Lavigne S, Addis A, Matsui D, Johnson Y, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003;48:106-10.
120. Chun?Fai?Chan B, Koren G, Fayez I, Kalra S, Voyer?Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am J Obstet Gynecol 2005;192:932-6.
121. Glaxosmithkline. The Bupropion Pregnancy Registry Final Report; 2008. Available from: http://www.pregnancyregistry.gsk.com/documents/bup- report-final-2008.pdf. [Last accessed on 2015 Mar 07].
122. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203:52.e1-6.
123. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:474-84.
124. Berga SL, Parry BL, Moses?Kolko EL. Psychiatry and reproductive medicine. In: Saddock BJ, Saddock VA, Ruiz P, editors. Kaplan and Sadocks's Comprehensive Text Book of Psychiatry. 9th ed., Vol. II. New York: Lippinkot William and Wilkins; 2009. p. 2539-62.
125. Creasy RK, Resnik R. Maternal?Fetal Medicine: Principles and Practice. 3rd ed. Philadelphia: WB Saunders; 1994. p. 96-7.
126. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998;44:77-87.
127. Cohen LS, Nonacs RM, Bailey JW, Viguera AC, Reminick AM, Altshuler LL, et al. Relapse of depression during pregnancy following antidepressant discontinuation: A preliminary prospective study. Arch Womens Ment Health 2004;7:217-21.
128. Singh S, Gulati S, Narang A, Bhakoo ON. Non?narcotic withdrawal syndrome in a neonate due to maternal clomipramine therapy. J Paediatr Child Health 1990;26:110.
129. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991;29:479-84.
130. Epperson CN, Ballew J. Postpartum depression: A common complication of childbirth. In: Hendrick V, editor. Psychiatric Disorders in Pregnancy and Postpartum: Principles and Treatment. Totowa, New Jersey: Humana Press; 2006. p. 41-83.
131. Moses?Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA 2005;293:2372-83.
132. Brioni JD, Orsingher OA. Operant behavior and reactivity to the anticonflict effect of diazepam in perinatally undernourished rats. Physiol Behav 1988;44:193-8.
133. Kellogg CK. Benzodiazepines: Influence on the developing brain. Prog Brain Res 1988;73:207-28.
134. Deutch AY, Gruen RJ, Roth RH. The effects of perinatal diazepam exposure on stress?induced activation of the mesotelencephalic dopamine system. Neuropsychopharmacology 1989;2:105-14.
135. De Salvia MA, Cagiano R, Lacomba C, Cuomo V. Neurobehavioral changes produced by developmental exposure to benzodiazepines. Dev Pharmacol Ther 1990;15:173-7.
136. Hartz SC, Heinonen OP, Shapiro S, Siskind V, Slone D. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975;292:726-8.
137. Laegreid L. Clinical observations in children after prenatal benzodiazepine exposure. Dev Pharmacol Ther 1990;15:186-8.
138. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 4th ed. Baltimore, MD: Williams and Wilkins; 1994.
139. Uzun S, Kozumplik O, Jakovljevic M, Sedic B. Side effects of treatment with benzodiazepines. Psychiatr Danub 2010;22:90-3.
140. Rosa FW, Baum C. Computerized on?line pharmaceutical surveillance system (COMPASS) teratology. Reprod Toxicol 1993;7:639-40.
141. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53:39-49.
142. Czeizel AE, Bod M, Halász P. Evaluation of anticonvulsant drugs during pregnancy in a population?based Hungarian study. Eur J Epidemiol 1992;8:122-7.
143. Sethi N, Manchana M. Maternal drug histories and congenital abnormalities. Indian J Psychiatry 1978;20:191-2.
144. Ghosh S, Bali L. Congenital malformations in the newborn. Indian J Child Health 1963;12:448-52.
145. Saifullah S, Chandra RK, Pathak IC, Dhall GI. Congenital malformations in new born. A prospective longitudinal study. A preliminary report on 1000 consecutive births. Indian Pediatr 1967;4:251-61.
146. Sharma B, Bajpai PC, Sharma NL. Some observations on congenital malformations. Indian J Pediatr 1972;39:286-92.
147. Buist A, Norman TR, Dennerstein L. Breastfeeding and the use of psychotropic medication: A review. J Affect Disord 1990;19:197-206.
148. Erickson SH, Smith GH, Heidrich F. Tricyclics and breast feeding. Am J Psychiatry 1979;136:1483-4.
149. Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant's serum. Am J Psychiatry 1980;137:855-6.
150. Brixen?Rasmussen L, Halgrener J, Jørgensen A. Amitriptyline and nortriptyline excretion in human breast milk. Psychopharmacology (Berl) 1982;76:94-5.
151. Pittard WB 3rd, O'Neal W Jr. Amitriptyline excretion in human milk. J Clin Psychopharmacol 1986;6:383-4.
152. Sovner R, Orsulak PJ. Excretion of imipramine and desipramine in human breast milk. Am J Psychiatry 1979;136:451-2.
153. Stancer HC, Reed KL. Desipramine and 2?hydroxydesipramine in human breast milk and the nursing infant's serum. Am J Psychiatry 1986;143:1597-600.
154. Kemp J, Ilett KF, Booth J, Hackett LP. Excretion of doxepin and N?desmethyldoxepin in human milk. Br J Clin Pharmacol 1985;20:497-9.
155. Matheson I, Pande H, Alertsen AR. Respiratory depression caused by N?desmethyldoxepin in breast milk. Lancet 1985;2:1124.
156. Frey OR, Scheidt P, von Brenndorff AI. Adverse effects in a newborn infant breast?fed by a mother treated with doxepin. Ann Pharmacother 1999;33:690-3.
157. Rees JA, Glass RC, Spome GA. Serum and breast milk concentrations of dothiepin. Practitioner 1976;217:686.
158. Gelenberg AJ. Single case study. Amoxapine, a new antidepressant, appears in human milk. J Nerv Ment Dis 1979;167:635-6.
159. Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol 1986;22:367-70.
160. Altshuler LL, Burt VK, McMullen M, Hendrick V. Breastfeeding and sertraline: A 24?hour analysis. J Clin Psychiatry 1995;56:243-5.
161. Mammen OK, Perel JM, Rudolph G, Foglia JP, Wheeler SB. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997;58:100-3.
162. Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997;154:1255-60.
163. Wisner KL, Perel JM, Blumer J. Serum sertraline and N?desmethylsertraline levels in breast?feeding mother?infant pairs. Am J Psychiatry 1998;155:690-2.
164. Kristensen JH, Ilett KF, Dusci LJ, Hackett LP, Yapp P, Wojnar?Horton RE, et al. Distribution and excretion of sertraline and N?desmethylsertraline in human milk. Br J Clin Pharmacol 1998;45:453-7.
165. Birnbaum CS, Cohen LS, Bailey JW, Grush LR, Robertson LM, Stowe ZN. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series. Pediatrics 1999;104:e11.
166. Dodd S, Stocky A, Buist A, Burrows GD, Norman TR. Sertraline analysis in the plasma of breast?fed infants. Aust N Z J Psychiatry 2001;35:545-6.
167. Epperson N, Czarkowski KA, Ward?O'Brien D, Weiss E, Gueorguieva R, Jatlow P, et al. Maternal sertraline treatment and serotonin transport in breast?feeding mother?infant pairs. Am J Psychiatry 2001;158:1631-7.
168. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163-6.
169. Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS, et al. The pharmacokinetics of sertraline excretion into human breast milk: Determinants of infant serum concentrations. J Clin Psychiatry 2003;64:73-80.
170. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992;89 (4 Pt 1):676-7.
171. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993;32:1253-5.
172. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996;36:42-7.
173. Yoshida K, Smith B, Craggs M, Kumar RC. Fluoxetine in breast?milk and developmental outcome of breast?fed infants. Br J Psychiatry 1998;172:175-8.
174. Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr (Phila) 1998;37:41-4.
175. Chambers CD, Anderson PO, Thomas RG, Dick LM, Felix RJ, Johnson KA, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999;104:e61.
176. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999;48:521-7.
177. Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL. Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry 2002;52:446-51.
178. Epperson CN, Jatlow PI, Czarkowski K, Anderson GM. Maternal fluoxetine treatment in the postpartum period: Effects on platelet serotonin and plasma drug levels in breastfeeding mother?infant pairs. Pediatrics 2003;112:e425.
179. Spigset O, Carleborg L, Norström A, Sandlund M. Paroxetine level in breast milk. J Clin Psychiatry 1996;57:39.
180. Begg EJ, Duffull SB, Saunders DA, Buttimore RC, Ilett KF, Hackett LP, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999;48:142-7.
181. Ohman R, Hägg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999;60:519-23.
182. Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry 2000;61:828-32.
183. Hendrick V, Stowe ZN, Altshuler LL, Hostetter A, Fukuchi A. Paroxetine use during breast?feeding. J Clin Psychopharmacol 2000;20:587-9.
184. Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000;157:185-9.
185. Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacother 1992;26:1563-5.
186. Jensen PN, Olesen OV, Bertelsen A, Linnet K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997;19:236-9.
187. Spigset O, Carieborg L, Ohman R, Norström A. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997;44:295-8.
188. Schmidt K, Olesen OV, Jensen PN. Citalopram and breast?feeding: Serum concentration and side effects in the infant. Biol Psychiatry 2000;47:164-5.
189. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 2000;50:263-8.
190. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72:184-91.
191. Lee A, Woo J, Ito S. Frequency of infant adverse events that are associated with citalopram use during breast?feeding. Am J Obstet Gynecol 2004;190:218-21.
192. Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. Br J Clin Pharmacol 1991;31:209.
193. Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast?milk. J Affect Disord 1997;43:225-37.
194. Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001;62:111-3.
195. Kristensen JH, Hackett LP, Kohan R, Paech M, Ilett KF. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact 2002;18:139-43.
196. Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. Ann Pharmacother 1993;27:431-3.
197. Baab SW, Peindl KS, Piontek CM, Wisner KL. Serum bupropion levels in 2 breastfeeding mother?infant pairs. J Clin Psychiatry 2002;63:910-1.
198. Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: A case of a possible infant seizure. J Clin Psychiatry 2004;65:881-2.
199. Hendrick V, Altshuler L, Wertheimer A, Dunn WA. Venlafaxine and breast?feeding. Am J Psychiatry 2001;158:2089-90.
200. Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O?desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002;53:17-22.
201. Hendrick V, Smith LM, Hwang S, Altshuler LL, Haynes D. Weight gain in breastfed infants of mothers taking antidepressant medications. J Clin Psychiatry 2003;64:410-2.
202. Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: Determination of exposure. J Clin Psychiatry 2009;70:1304-10.
203. Weissman AM, Levy BT, Hartz AJ, Bentler S, Donohue M, Ellingrod VL, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 2004;161:1066-78.
204. Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol 2009;52:483-97.
205. Berle JØ, Spigset O. Maternal antidepressant use and breastfeeding. Curr Med Lit Psychiatry 2008;19:33-7.
206. Gentile S. Use of contemporary antidepressants during breastfeeding: A proposal for a specific safety index. Drug Saf 2007;30:107-21.
207. Ragan K, Stowe ZN, Newport DJ. Use of antidepressants and mood stabilizers in breast?feeding women. In: Cohen LS, Nonacs RM, editors. Mood and Anxiety Disorders During Pregnancy and Postpartum.(Review of Psychiatry Series, Volume 24, Number 4; Oldham JM and Riba MB, series editors). Washington, DC: American Psychiatric Publishing; 2005. p. 105-44.
208. National Collaborating Centre for Mental Health. NICE Guideline on Clinical Management and Service Guidance. Antenatal and Postnatal Mental Health. No. 45; 2007. Available from: http://www.nice.org.uk/ nicemedia/pdf/CG45fullguideline.pdf. [Last accessed on 2010 Jan 31].
209. Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #18: Use of antidepressants in nursing mothers. Breastfeed Med 2008;3:44-52.
210. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: Clinical management guidelines for obstetrician?gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007).
211. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008;111:1001-20.
212. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev 2011;7:28-34.
213. Patrick MJ, Tilstone WJ, Reavey P. Diazepam and breast?feeding. Lancet 1972;1:542-3.
214. Wretlind M. Excretion of oxazepam in breast milk. Eur J Clin Pharmacol 1987;33:209-10.
215. Stebler T, Guentert TW. Determination of diazepam and nordazepam in milk and plasma in the presence of oxazepam and temazepam. J Chromatogr 1991;564:330-7.
216. Oo CY, Kuhn RJ, Desai N, Wright CE, McNamara PJ. Pharmacokinetics in lactating women: Prediction of alprazolam transfer into milk. Br J Clin Pharmacol 1995;40:231-6.
217. Erkkola R, Kanto J. Diazepam and breast?feeding. Lancet 1972;1:1235-6.
218. Brandt R. Passage of diazepam and desmethyldiazepam into breast milk. Arzneimittelforschung 1976;26:454-7.
219. Summerfield RJ, Nielsen MS. Excretion of lorazepam into breast milk. Br J Anaesth 1985;57:1042-3.
220. Hümpel M, Stoppelli I, Milia S, Rainer E. Pharmacokinetics and biotransformation of the new benzodiazepine, lormetazepam, in man. III. Repeated administration and transfer to neonates via breast milk. Eur J Clin Pharmacol 1982;21:421-5.
221. Hilbert JM, Gural RP, Symchowicz S, Zampaglione N. Excretion of quazepam into human breast milk. J Clin Pharmacol 1984;24:457-62.
222. Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed) 1981;282:1106-8.
223. Reider J, Wendt G. Pharmacokinetics and metabolism of the hypnotic nitrazepam. In: Garattini S, Mussini E, Randall LO, editors. The Benzodiazepines. New York, NY: Raven Press; 1973. p. 99-127.
224. Kanto J, Aaltonen L, Kangas L, Erkkola R, Pitkanen Y. Placental transfer and breast milk levels of flunitrazepam. Curr Ther Res 1979;26:539-46.
225. Pons G, Francoual C, Guillet P, Moran C, Hermann P, Bianchetti G, et al. Zolpidem excretion in breast milk. Eur J Clin Pharmacol 1989;37:245-8.
226. Darwish M, Martin PT, Cevallos WH, Tse S, Wheeler S, Troy SM. Rapid disappearance of zaleplon from breast milk after oral administration to lactating women. J Clin Pharmacol 1999;39:670-4.
227. Dusci LJ, Good SM, Hall RW, Ilett KF. Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. Br J Clin Pharmacol 1990;29:123-6.
228. Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010;31:60-5.